FDA Greenlights Salt Swaps in Your Favorite Foods
Published Date: 10/13/2026
Rule
Summary
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Salt substitutes allowed in many foods
The FDA now permits the use of safe and suitable salt substitutes to replace some or all added salt in standardized foods. The final rule amends 80 standards of identity directly and, via cross-references, permits salt substitutes in a total of 139 standards of identity; the rule takes effect December 14, 2026.
No regulatory mandate but reformulation costs possible
FDA says there are no regulatory costs because manufacturers are not required to use salt substitutes, but companies that voluntarily reformulate products to use salt substitutes may incur reformulation and relabeling costs and may face potential consumer dissatisfaction. The rule is voluntary and effective December 14, 2026.
Salt substitutes still subject to safety rules
Ingredients used as salt substitutes must comply with the Federal Food, Drug, and Cosmetic Act; if a substitute is a food additive it requires premarket approval under section 409. The final rule does not authorize or exempt ingredients from food additive requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20817, Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers; Guidance for Industry; Availability
The FDA just released clear answers for companies making changes to biosimilar medicines after approval. This helps drug makers keep their products safe and effective without delays or extra costs. If you’re involved in biosimilar production, this guidance is your new go-to for smooth updates and staying on track with the rules.
Previous / Next Documents
Previous: 2026-20847, Amendment of United States Area Navigation (RNAV) Route T-437; Eastern United States
The FAA is updating RNAV Route T-437 in the eastern U.S. to make flying safer and smoother as part of their NextGen plan. Pilots and airlines flying this route will see changes starting December 24, 2026, with no extra costs involved. This upgrade helps keep our skies modern and efficient for everyone.
Next: 2026-20849, Clean Water Act Hazardous Substance Facility Response Plans: Compliance Date Delay and Changes To Reflect Administration Policy
The EPA is giving facilities more time to meet new Clean Water Act rules for handling hazardous spills, pushing back the deadline to help them get ready. They’re also removing mentions of climate change and environmental justice to match new government policies. This delay helps facilities plan better without rushing and lets the EPA rethink the rules if needed.